½ÃÀ庸°í¼­
»óǰÄÚµå
1611988

¼¼°èÀÇ ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå : Á¦Ç° À¯Çüº°, °Ë»ç À¯Çüº°, Áúȯ À¯Çüº°, ±â¼úº°, ÃÖÁ¾ »ç¿ëÀÚº° - ¿¹Ãø(2025-2030³â)

Acute Ischemic Stroke Diagnosis Market by Product Type (Blood Biomarker, Carotid Ultrasound, Diagnostic Imaging), Test Type (Imaging Tests, Lab Tests), Disease Type, Technology, End Users - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀº 2023³â¿¡ 35¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 37¾ï 7,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, CAGR 6.61%·Î ¼ºÀåÇÒ Àü¸ÁÀ̰í, 2030³â¿¡´Â 55¾ï 9,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´ÜÀÇ ´ë»óÀº ÁÖ·Î ³ú·ÎÀÇ Ç÷·ù¸¦ Á¦ÇÑÇÏ´Â Æó»öÀ¸·Î ÀÎÇÑ ÇãÇ÷¼º ³úÁ¹Áß È¯ÀÚÀÇ ½Äº°°ú Æò°¡ÀÔ´Ï´Ù. Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´ÜÀÇ Çʿ伺Àº Ç÷·ù¸¦ ȸº¹½ÃŰ°í ³úÀÇ ¼Õ»óÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ½Ã°£ÀÌ Áß¿äÇÑ ³úÁ¹Áß Ä¡·áÀÇ ±ä±Þ¼º¿¡ ±âÀÎÇÕ´Ï´Ù. ¿ëµµ´Â ±¸±ÞºÎ, º´¿ø, ³úÁ¹Áß Àü¹®¼¾ÅÍ¿¡±îÁö À̸£¸ç ÇãÇ÷¼º ³úÁ¹Áß°ú ÃâÇ÷¼º ³úÁ¹ÁßÀ» ±¸º°Çϱâ À§ÇÑ CT³ª MRI ½ºÄµ µîÀÇ °í±Þ È­»ó Áø´Ü ±â¼ú¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ÀÇ·á Àü¹®°¡, º´¿ø, ¿¬±¸ ±â°ü, ÀÇ·á±â±â Á¦Á¶¾÷ü¿¡ Àåºñ ¹× Áø´Ü µµ±¸¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¼ºÀå¿¡ ¿µÇâÀ» ÁÖ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â °í·ÉÈ­¿Í ¶óÀÌÇÁ½ºÅ¸ÀÏ º¯È­¿¡ µû¸¥ ³úÁ¹Áß À¯º´·ü Áõ°¡, ¿µ»ó±â¼úÀÇ Áøº¸, ÇコÄɾî ÀÎÇÁ¶ó °³¼± µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª Áø´Ü±â±âÀÇ °íºñ¿ë°ú ÇコÄÉ¾î °ÝÂ÷°¡ ½ÃÀå ¼ºÀåÀÇ Á¦¾à ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå °³Ã´ÀÇ ±âȸ´Â ÈÞ´ë°¡ °¡´ÉÇϰí ÀÌ¿ëÀÌ Æí¸®ÇÑ Áø´Ü±â¼ú °³¹ß, Á¶±â¹ß°ßÀ» À§ÇÑ ÀΰøÁö´É ÀÌ¿ë, ¿ø°ÝÀÇ·á, ÀÇ·áÁ¦µµ°¡ ¹ÌÈíÇÑ ½ÅÈï±¹ ½ÃÀå ÁøÃ⠵ ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Áø´Ü µµ±¸³ª AI ¾Ë°í¸®Áò ¿¬±¸¿¡ ÅõÀÚÇÏ´Â ±â¾÷Àº °æÀï»óÀÇ ¿ìÀ§¼ºÀ» ȹµæÇÒ ¼ö ÀÖÀ» °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ±×·¸´Ù°í´Â ÇØµµ Àü¹®ÀûÀÎ ³ëµ¿·ÂÀÇ Çʿ伺, ±ÔÁ¦»óÀÇ Àå¾Ö¹°, AI ÅëÇÕ°ú °ü·ÃµÈ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹®Á¦ µîÀÇ °úÁ¦¿¡ ´ëóÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. »ç¾÷ ¼ºÀå °üÁ¡¿¡¼­ÀÇ Çõ½ÅÀº Áø´Ü ½Ã½ºÅÛÀÇ »óÈ£ ¿î¿ë¼º °­È­, Áø´ÜÀÇ Á¤È®¼º°ú ¼Óµµ Çâ»ó, µðÁöÅÐ Çコ ½ÅÈï ±â¾÷°úÀÇ Á¦ÈÞ ¸ð»ö¿¡ ÃÊÁ¡À» ¸ÂÃâ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ½ÃÀåÀº ±Þ¼ÓÇÑ ±â¼ú ÁøÈ­¿Í °æÀï ¾Ð·ÂÀ¸·Î Ư¡Áö¾îÁö¸ç, ±â¾÷Àº ½ÃÀå Æ÷Áö¼ÇÀ» À¯ÁöÇϱâ À§ÇØ Áö¼ÓÀûÀÎ Çõ½ÅÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ÃÖÀûÀÇ »ç¾÷ ¼ºÀåÀ» À§Çؼ­ ÀÌÇØ°ü°èÀÚ´Â Àü·«Àû Á¦ÈÞ, ÃÖ÷´Ü ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ, ƯÁ¤ Áö¿ªÀÇ ¼ö¿ä ¸ÂÃãÇü ½ÃÀå È®´ë ÀÌ´Ï¼ÅÆ¼ºê¸¦ Áß½ÃÇÏ°í ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀÇ ÀáÀçÀû ±âȸ¸¦ ÃÖ´ëÇÑ È°¿ëÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023³â) 35¾ï 7,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024³â) 37¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 55¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 6.61%

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½É±Ù °æ»öÀÇ ÀÌȯÀ² Áõ°¡, °íµµÀÇ Áø´Ü Åø¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
    • °³¹ß µµ»ó Áö¿ªÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶ó ÅõÀÚ È®´ë
    • ½ÃÀÇ ÀûÀýÇÑ ÀÇ·á °³ÀÔ°ú Á¶±â Áø´Ü °Ë»çÀÇ Á߿伺¿¡ ´ëÇÑ ÀÇ½Ä °íÁ¶
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • °³¹ß µµ»ó Áö¿ª¿¡¼­ Áø´Ü óġÀÇ °íºñ¿ë°ú ÷´Ü ÀÇ·á¿¡ ´ëÇÑ ¾×¼¼½ºÀÇ Á¦ÇÑ
  • ½ÃÀå ±âȸ
    • °íµµ Áø´ÜÀ» À§ÇÑ ·Îº¿ °øÇаú AIÀÇ ÅëÇÕ
    • ¿ø°Ý Áø´Ü°ú Á¶±â °³ÀÔÀ» ÃËÁøÇÏ´Â ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ Áøº¸
  • ½ÃÀåÀÇ °úÁ¦
    • ¼÷·ÃµÈ ÇコÄɾî Àü¹®°¡ÀÇ ºÎÁ·

Porter's Five Forces : ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲÀÇ °æÀï ±¸µµ¸¦ ÆÄ¾ÇÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®¸¦ ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× Ãßõ : ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸®±â

±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇöÀå °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·ÂÀ» Æò°¡ÇÕ´Ï´Ù.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð ¹× ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ ¹× ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À² ¹× °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ½ÉÀå ¹ßÀÛ ¹ß»ý·ü Áõ°¡ ¹× ÷´Ü Áø´Ü ÅøÀÇ Çʿ伺 Áõ°¡
      • °³¹ß µµ»ó Áö¿ªÀÇ °Ç°­ °ü¸® ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡
      • ½Ã±â ÀûÀýÇÑ ÀÇ·á °³ÀÔ°ú Á¶±â Áø´Ü °Ë»çÀÇ Á߿伺¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡
    • ¾ïÁ¦¿äÀÎ
      • °³¹ß µµ»ó Áö¿ª¿¡¼­ Áø´Ü ÀýÂ÷ÀÇ °íºñ¿ë ¹× °íµµÀÇ °Ç°­ °ü¸®¿¡ ´ëÇÑ ¾×¼¼½º Á¦ÇÑ
    • ±âȸ
      • °í±Þ Áø´ÜÀ» À§ÇÑ ·Îº¿°ú AIÀÇ ÅëÇÕ
      • ¿ø°Ý Áø´Ü°ú Á¶±â °³ÀÔÀ» ÃËÁøÇÏ´Â ¿ø°Ý ÀÇ·á ¼­ºñ½ºÀÇ Áøº¸
    • °úÁ¦
      • ¼÷·ÃµÈ ÇコÄɾî Á¾»çÀÚÀÇ ºÎÁ·
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Á¦Ç° À¯Çüº° : ³ú ¼Õ»óÀÇ Á¶±â ¹ß°ßÀ» À§ÇÑ Ç÷¾× ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ÀÌ¿ë Áõ°¡
    • ÃÖÁ¾ ¿ëµµº° : ÁýÁß ¸ð´ÏÅ͸µÀ» À§ÇÑ ÀÔ¿ø ¼­ºñ½º¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå : Á¦Ç° À¯Çüº°

  • Ç÷¾×¹ÙÀÌ¿À¸¶Ä¿
  • °æµ¿¸Æ ÃÊÀ½ÆÄ °Ë»ç
  • Áø´Ü À̹ÌÁö
    • ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ(CT) ½ºÄ³³Ê
    • MRI ½Ã½ºÅÛ
  • ³úÆÄ °Ë»ç

Á¦7Àå ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå : Å×½ºÆ® À¯Çüº°

  • È­»ó °Ë»ç
  • ½ÇÇè½Ç Å×½ºÆ®
    • Ç÷¾×°Ë»ç
    • ´ë»ç ÆÐ³Î

Á¦8Àå ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå : Áúȯ À¯Çüº°

  • »öÀü
  • ¶óÄí³ª
  • Ç÷Àü¼º

Á¦9Àå ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå : ±â¼úº°

  • ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý °ËÃâ
  • Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç

Á¦10Àå ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Áø´Ü¼¾ÅÍ
  • º´¿ø
    • ÀÔ¿øÈ¯ÀÚ
    • ¿Ü·¡È¯ÀÚ
  • ¿¬±¸±â°ü

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • StrokeDx, ºñħ½À¼º ³úÁ¹Áß °ËÃâ ±â¼úÀÇ °­È­¿Í ½ÃÀå ¹üÀ§ÀÇ È®´ë¸¦ À§ÇØ 500¸¸ ´Þ·¯ÀÇ ÀÚ±ÝÀ» È®º¸
    • Áß±¹ Àǰú´ëÇк´¿øÀÇ AISIA AI Ç÷§ÆûÀº ºü¸£°í Á¤È®ÇÏ¸ç ¹Î°¨ÇÑ µö·¯´× ¸ðµ¨À» ÅëÇØ ÇãÇ÷¼º ³úÁ¹Áß Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ È¯ÀÚ °á°ú¸¦ °³¼±Çϰí Àå±âÀûÀÎ ºñ¿ëÀ» Àý°¨ÇÕ´Ï´Ù.
    • CERENOVUS»ç, TruCourse Å×Å©³î·ÎÁö¸¦ žÀçÇÑ CEREGLIDE 71 Áß°£ Ä«Å×Å͸¦ ¹ß¸Å, ±Þ¼º ÇãÇ÷¼º ³úÁ¹Áß Ä¡·áÀÇ Áøº¸¿¡ °øÇå
  • Àü·« ºÐ¼® ¹× Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abbott Laboratories
  • BIOTRONIK SE & Co KG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE Healthcare Technologies Inc.
  • Genentech, Inc. by Roche Group
  • Hitachi, Ltd.
  • Integral Diagnostics(IDX)Group
  • Koninklijke Philips NV
  • Mediso Kft.
  • Medtronic PLC
  • Memorial Health
  • Neusoft Medical Systems Co., Ltd.
  • Nihon Kohden Corporation
  • Planmed Oy
  • Samsung Electronics Co. Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers company
  • Stryker Corporation
  • Toshiba International Corporation
AJY 24.12.24

The Acute Ischemic Stroke Diagnosis Market was valued at USD 3.57 billion in 2023, expected to reach USD 3.77 billion in 2024, and is projected to grow at a CAGR of 6.61%, to USD 5.59 billion by 2030.

The scope of acute ischemic stroke diagnosis involves identifying and evaluating patients experiencing ischemic strokes, primarily caused by blockages restricting blood flow to the brain. The necessity for accurate and rapid diagnosis stems from the urgent nature of stroke treatment, where time is critical to restore blood flow and minimize brain damage. The applications extend to emergency departments, hospitals, and specialized stroke centers, focusing on advanced imaging technologies like CT and MRI scans to differentiate between ischemic and hemorrhagic strokes. This market serves healthcare professionals, hospitals, research institutions, and medical device manufacturers with equipment and diagnostic tools. Key factors influencing growth include the increasing prevalence of strokes due to aging populations and lifestyle changes, advancements in imaging technology, and improved healthcare infrastructure. However, the high cost of diagnostic equipment and healthcare disparities pose limitations to market growth. Opportunities lie in the development of portable and accessible diagnostic technologies, use of artificial intelligence for early detection, telemedicine, and expansion into emerging markets with inadequate healthcare systems. Companies investing in research for non-invasive diagnostic tools and AI algorithms may gain competitive advantages. Nonetheless, challenges such as the need for specialized workforce, regulatory hurdles, and data privacy issues related to AI integration must be addressed. Innovation from a business growth perspective could focus on enhancing the interoperability of diagnostic systems, improving accuracy and speed of diagnosis, and exploring partnerships with digital health startups. The market is characterized by rapid technological evolution and competitive pressures requiring companies to continuously innovate to maintain market positions. For optimal business growth, stakeholders should emphasize strategic collaborations, investment in cutting-edge technologies, and market expansion initiatives tailored to specific regional demands to harness the full potential of opportunities in the acute ischemic stroke diagnosis market.

KEY MARKET STATISTICS
Base Year [2023] USD 3.57 billion
Estimated Year [2024] USD 3.77 billion
Forecast Year [2030] USD 5.59 billion
CAGR (%) 6.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Ischemic Stroke Diagnosis Market

The Acute Ischemic Stroke Diagnosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing incidence of cardiac strokes, enhancing need for advanced diagnostic tools
    • Growing investment in healthcare infrastructure in developing regions
    • Rising awareness about the importance of timely medical intervention and earlier diagnostic testing
  • Market Restraints
    • High cost of diagnostic procedures and limited access to advanced healthcare in developing regions
  • Market Opportunities
    • Integration of robotics and AI for advanced diagnostics
    • Advancement in telemedicine services facilitating remote diagnosis and early intervention
  • Market Challenges
    • Shortage of skilled healthcare professionals

Porter's Five Forces: A Strategic Tool for Navigating the Acute Ischemic Stroke Diagnosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Ischemic Stroke Diagnosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Ischemic Stroke Diagnosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Ischemic Stroke Diagnosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Ischemic Stroke Diagnosis Market

A detailed market share analysis in the Acute Ischemic Stroke Diagnosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Ischemic Stroke Diagnosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Ischemic Stroke Diagnosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Ischemic Stroke Diagnosis Market

A strategic analysis of the Acute Ischemic Stroke Diagnosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Ischemic Stroke Diagnosis Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BIOTRONIK SE & Co KG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Canon Medical Systems Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE Healthcare Technologies Inc., Genentech, Inc. by Roche Group, Hitachi, Ltd., Integral Diagnostics (IDX) Group, Koninklijke Philips N.V., Mediso Kft., Medtronic PLC, Memorial Health, Neusoft Medical Systems Co., Ltd., Nihon Kohden Corporation, Planmed Oy, Samsung Electronics Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shimadzu Corporation, Siemens Healthineers company, Stryker Corporation, and Toshiba International Corporation.

Market Segmentation & Coverage

This research report categorizes the Acute Ischemic Stroke Diagnosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Blood Biomarker, Carotid Ultrasound, Diagnostic Imaging, and Electroencephalography. The Diagnostic Imaging is further studied across Computed Tomography (CT) Scanner and MRI System.
  • Based on Test Type, market is studied across Imaging Tests and Lab Tests. The Lab Tests is further studied across Blood Test and Metabolic Panel.
  • Based on Disease Type, market is studied across Embolic, Lacunar, and Thrombotic.
  • Based on Technology, market is studied across Biomarker-Based Detection and Point Of Care Testing.
  • Based on End Users, market is studied across Ambulatory Surgical Centers, Diagnostic Centers, Hospitals, and Research Institutes. The Hospitals is further studied across Inpatient and Outpatient.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of cardiac strokes, enhancing need for advanced diagnostic tools
      • 5.1.1.2. Growing investment in healthcare infrastructure in developing regions
      • 5.1.1.3. Rising awareness about the importance of timely medical intervention and earlier diagnostic testing
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diagnostic procedures and limited access to advanced healthcare in developing regions
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of robotics and AI for advanced diagnostics
      • 5.1.3.2. Advancement in telemedicine services facilitating remote diagnosis and early intervention
    • 5.1.4. Challenges
      • 5.1.4.1. Shortage of skilled healthcare professionals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Growing usage of blood biomarkers for early detection of brain injury
    • 5.2.2. End Use: Rising need of inpatient services for intensive monitoring
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Ischemic Stroke Diagnosis Market, by Product Type

  • 6.1. Introduction
  • 6.2. Blood Biomarker
  • 6.3. Carotid Ultrasound
  • 6.4. Diagnostic Imaging
    • 6.4.1. Computed Tomography (CT) Scanner
    • 6.4.2. MRI System
  • 6.5. Electroencephalography

7. Acute Ischemic Stroke Diagnosis Market, by Test Type

  • 7.1. Introduction
  • 7.2. Imaging Tests
  • 7.3. Lab Tests
    • 7.3.1. Blood Test
    • 7.3.2. Metabolic Panel

8. Acute Ischemic Stroke Diagnosis Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Embolic
  • 8.3. Lacunar
  • 8.4. Thrombotic

9. Acute Ischemic Stroke Diagnosis Market, by Technology

  • 9.1. Introduction
  • 9.2. Biomarker-Based Detection
  • 9.3. Point Of Care Testing

10. Acute Ischemic Stroke Diagnosis Market, by End Users

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Diagnostic Centers
  • 10.4. Hospitals
    • 10.4.1. Inpatient
    • 10.4.2. Outpatient
  • 10.5. Research Institutes

11. Americas Acute Ischemic Stroke Diagnosis Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Acute Ischemic Stroke Diagnosis Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Acute Ischemic Stroke Diagnosis Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. StrokeDx secures USD 5M funding to enhance non-invasive stroke detection technology and expand market reach
    • 14.3.2. China Medical University Hospital's AISIA AI platform revolutionizes ischemic stroke diagnosis with rapid, accurate, and sensitive deep learning models, enhancing patient outcomes and reducing long-term costs
    • 14.3.3. CERENOVUS launches CEREGLIDE 71 Intermediate Catheter with TruCourse technology, advancing acute ischemic stroke treatment
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. BIOTRONIK SE & Co KG
  • 3. Boehringer Ingelheim International GmbH
  • 4. Boston Scientific Corporation
  • 5. Canon Medical Systems Corporation
  • 6. F. Hoffmann-La Roche Ltd.
  • 7. Fujifilm Holdings Corporation
  • 8. GE Healthcare Technologies Inc.
  • 9. Genentech, Inc. by Roche Group
  • 10. Hitachi, Ltd.
  • 11. Integral Diagnostics (IDX) Group
  • 12. Koninklijke Philips N.V.
  • 13. Mediso Kft.
  • 14. Medtronic PLC
  • 15. Memorial Health
  • 16. Neusoft Medical Systems Co., Ltd.
  • 17. Nihon Kohden Corporation
  • 18. Planmed Oy
  • 19. Samsung Electronics Co. Ltd.
  • 20. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 21. Shimadzu Corporation
  • 22. Siemens Healthineers company
  • 23. Stryker Corporation
  • 24. Toshiba International Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦